Sulfonylureas: Available Agents and Dosing
The second-generation sulfonylureas currently used in clinical practice are glipizide, glimepiride, and glyburide, with glipizide and glimepiride being the preferred agents due to lower hypoglycemia risk, particularly in patients with chronic kidney disease. 1
Available Second-Generation Sulfonylureas
The three main second-generation sulfonylureas in current use are:
- Glipizide (pancreas-specific, short-acting)
- Glimepiride (pancreas-nonspecific, long-acting)
- Glyburide (pancreas-nonspecific, long-acting)
Recommended Dosing Regimens
Glipizide
- Starting dose: 5 mg once daily
- Maintenance dose: 5-20 mg/day
- Maximum dose: 40 mg/day (divided doses if >15 mg/day)
- Extended-release formulation available for once-daily dosing
Glimepiride
- Starting dose: 1-2 mg once daily
- Maintenance dose: 1-4 mg/day
- Maximum dose: 8 mg/day
- Once-daily dosing 3
Glyburide
- Starting dose: 2.5-5 mg once daily
- Maintenance dose: 2.5-20 mg/day
- Maximum dose: 20 mg/day (divided doses if >10 mg/day)
Critical Dosing Considerations by Clinical Context
Chronic Kidney Disease
Glyburide is generally not recommended in CKD due to increased hypoglycemia risk. Glipizide and glimepiride should be initiated conservatively with lower starting doses to avoid hypoglycemia. 1
Hypoglycemia Risk Stratification
Glyburide and glimepiride (nonspecific, long-acting agents) carry a 2.83-fold increased risk of severe hypoglycemia compared to glipizide (specific, short-acting agent). 5 This makes glipizide the safer choice in elderly patients, those with irregular meal patterns, or those at high hypoglycemia risk.
Cardiovascular Safety
Glimepiride has been shown to be cardiovascular safe, addressing historical FDA concerns about increased CV mortality with older sulfonylureas like tolbutamide. 1 Nonspecific, long-acting sulfonylureas (glyburide/glimepiride) do not increase cardiovascular events compared to specific, short-acting agents. 5
Key Clinical Pitfalls and Precautions
When Starting Sulfonylureas
- Monitor fasting glucose and A1C to determine optimal dosing for each patient 2
- Initiate at lower doses in elderly, frail patients, or those with renal impairment 1
- Avoid in patients with irregular eating patterns or high hypoglycemia risk
When Combining with Insulin
Reassess sulfonylurea dose or discontinue when initiating insulin therapy to minimize hypoglycemia risk and treatment burden. 6 The combination increases hypoglycemia risk substantially, particularly with glyburide.
Monitoring Requirements
- Watch for hypoglycemia (most common adverse effect, varies by agent)
- Assess for weight gain (expected with all sulfonylureas) 1
- Monitor for progressive loss of effectiveness over time due to declining beta-cell function 4
Practical Switching Strategies
When transitioning between sulfonylureas or to combination therapy, monitor closely for hypoglycemia during the first 1-2 weeks. Fasting glucose should be checked frequently to optimize dosing. 2 Consider starting at lower equivalent doses when switching to glyburide or glimepiride given their higher hypoglycemia risk.
Contemporary Role in Treatment Algorithm
Sulfonylureas remain important as lower-cost options when financial barriers exist, but should be used within the context of their risks for hypoglycemia and weight gain. 6 They are most appropriately used in combination with metformin when newer agents (GLP-1 RAs, SGLT2 inhibitors) are not accessible or appropriate, though these newer agents are generally preferred for their cardiovascular and renal benefits. 1, 6